CN103298345B - 组合 - Google Patents
组合 Download PDFInfo
- Publication number
- CN103298345B CN103298345B CN201280004830.0A CN201280004830A CN103298345B CN 103298345 B CN103298345 B CN 103298345B CN 201280004830 A CN201280004830 A CN 201280004830A CN 103298345 B CN103298345 B CN 103298345B
- Authority
- CN
- China
- Prior art keywords
- methyl
- chloro
- compound
- administered
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GXJABQQUPOEUTA-RDJZCZTQSA-N CC(C)C[C@@H](B(O)O)NC([C@H](Cc1ccccc1)NC(c1nccnc1)=O)=O Chemical compound CC(C)C[C@@H](B(O)O)NC([C@H](Cc1ccccc1)NC(c1nccnc1)=O)=O GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- LNIFEKHXOSXTPP-GCRRARIESA-N CN/C(/c(cc(C(N[C@@H](Cc1cc(F)ccc1)CN)=O)[s]1)c1Cl)=C(\C=N)/Cl Chemical compound CN/C(/c(cc(C(N[C@@H](Cc1cc(F)ccc1)CN)=O)[s]1)c1Cl)=C(\C=N)/Cl LNIFEKHXOSXTPP-GCRRARIESA-N 0.000 description 1
- ZEESWPRDQGWOMU-AWEZNQCLSA-N Cc([s]c(C(N[C@@H](Cc1cccc(F)c1)CN)=O)c1)c1-c([n](C)nc1)c1Cl Chemical compound Cc([s]c(C(N[C@@H](Cc1cccc(F)c1)CN)=O)c1)c1-c([n](C)nc1)c1Cl ZEESWPRDQGWOMU-AWEZNQCLSA-N 0.000 description 1
- ULDXWLCXEDXJGE-UHFFFAOYSA-N NC1(CCC1)c(cc1)ccc1-c(c(-c1ccccc1)c1)nc(C=CN23)c1C2=NNC3=O Chemical compound NC1(CCC1)c(cc1)ccc1-c(c(-c1ccccc1)c1)nc(C=CN23)c1C2=NNC3=O ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 1
- GAMHLKCZDZGCFT-NHUVNFLLSA-N Oc1cc(O)c(CC(CC(c(cc2O)cc(O)c2O)=O)[C@@H](c(cc2O)cc(O)c2O)O2)c2c1 Chemical compound Oc1cc(O)c(CC(CC(c(cc2O)cc(O)c2O)=O)[C@@H](c(cc2O)cc(O)c2O)O2)c2c1 GAMHLKCZDZGCFT-NHUVNFLLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431508P | 2011-01-11 | 2011-01-11 | |
| US61/431,508 | 2011-01-11 | ||
| PCT/US2012/020863 WO2012097021A1 (en) | 2011-01-11 | 2012-01-11 | Combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103298345A CN103298345A (zh) | 2013-09-11 |
| CN103298345B true CN103298345B (zh) | 2016-12-14 |
Family
ID=46507420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280004830.0A Active CN103298345B (zh) | 2011-01-11 | 2012-01-11 | 组合 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US20130288984A1 (https=) |
| EP (1) | EP2663189B1 (https=) |
| JP (1) | JP6100700B2 (https=) |
| KR (1) | KR20140053836A (https=) |
| CN (1) | CN103298345B (https=) |
| AU (1) | AU2012205601B2 (https=) |
| BR (1) | BR112013017722A2 (https=) |
| CA (1) | CA2824201A1 (https=) |
| EA (1) | EA029000B1 (https=) |
| ES (1) | ES2689760T3 (https=) |
| IL (1) | IL227097B (https=) |
| MX (1) | MX356704B (https=) |
| SG (2) | SG191724A1 (https=) |
| WO (1) | WO2012097021A1 (https=) |
| ZA (1) | ZA201304139B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3063787T3 (en) * | 2013-10-01 | 2026-04-20 | Novartis Ag | Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor |
| WO2015069266A1 (en) * | 2013-11-07 | 2015-05-14 | Flynn Daniel L | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| PT4013412T (pt) | 2019-08-12 | 2026-03-18 | Deciphera Pharmaceuticals Llc | Ripretinib para o tratamento de tumores estromais gastrointestinais |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6328590B1 (en) | 2000-07-20 | 2001-12-11 | Emc Corporation | Methods and apparatus for controlling attachment of an electronic module with a circuit board connector |
| WO2005095387A1 (en) * | 2004-03-24 | 2005-10-13 | Abbott Laboratories | Tricyclic pyrazole kinase inhibitors |
| EP2708531A1 (en) | 2004-10-13 | 2014-03-19 | Pharmacia & Upjohn Company LLC | Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP1928437A2 (en) * | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1840114A1 (en) | 2006-03-30 | 2007-10-03 | LTB4 Sweden AB | Crystalline Leukotriene B4 |
| AU2007234379A1 (en) | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| WO2007122686A1 (ja) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| EP3804730A1 (en) | 2006-08-25 | 2021-04-14 | Janssen Oncology, Inc. | Compositions for treating cancer |
| JP4299327B2 (ja) | 2006-08-31 | 2009-07-22 | トヨタ自動車株式会社 | 可変バルブタイミング装置 |
| WO2008094321A2 (en) | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Akt sensitization of cancer cells |
| MY149140A (en) | 2006-10-13 | 2013-07-15 | Basf Se | Hydrates of 2-chloro 5-y3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoro-methyl)-1-(2h)-pyrimidinyl"-4-fluoro-n- yymethyl-(1-methylethyl)-amino"sulphonyl"benzamide |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| DE102008044901A1 (de) | 2008-08-29 | 2010-03-04 | Siemens Aktiengesellschaft | Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage |
| US20110288142A1 (en) | 2009-01-30 | 2011-11-24 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| UY32730A (es) | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| BR112012008274A2 (pt) | 2009-10-08 | 2015-09-22 | Glaxosmithkline Llc | combinação |
| KR102021157B1 (ko) | 2011-04-01 | 2019-09-11 | 제넨테크, 인크. | Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법 |
| WO2012151413A1 (en) | 2011-05-03 | 2012-11-08 | University Of Rochester | Methods for treating prostate cancer |
| US9138436B2 (en) | 2011-07-13 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| RS55223B1 (sr) | 2011-10-10 | 2017-02-28 | Zach System | Postupak za dobijanje 17-supstituisanih steroida |
| PH12014500943A1 (en) | 2011-11-30 | 2014-06-30 | Astrazeneca Ab | Combination treatment of cancer |
| JO3754B1 (ar) | 2012-06-04 | 2021-01-31 | Pharmacyclics Llc | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
| JP6355724B2 (ja) | 2013-10-01 | 2018-07-11 | ノバルティス アーゲー | がんを治療するためのアフレセルチブと組み合わせたエンザルタミド |
-
2012
- 2012-01-11 JP JP2013549503A patent/JP6100700B2/ja active Active
- 2012-01-11 AU AU2012205601A patent/AU2012205601B2/en not_active Ceased
- 2012-01-11 SG SG2013043856A patent/SG191724A1/en unknown
- 2012-01-11 EA EA201391027A patent/EA029000B1/ru not_active IP Right Cessation
- 2012-01-11 KR KR1020137021098A patent/KR20140053836A/ko not_active Abandoned
- 2012-01-11 WO PCT/US2012/020863 patent/WO2012097021A1/en not_active Ceased
- 2012-01-11 CN CN201280004830.0A patent/CN103298345B/zh active Active
- 2012-01-11 MX MX2013008074A patent/MX356704B/es active IP Right Grant
- 2012-01-11 BR BR112013017722A patent/BR112013017722A2/pt not_active IP Right Cessation
- 2012-01-11 ES ES12733916.6T patent/ES2689760T3/es active Active
- 2012-01-11 CA CA2824201A patent/CA2824201A1/en not_active Abandoned
- 2012-01-11 US US13/978,765 patent/US20130288984A1/en not_active Abandoned
- 2012-01-11 EP EP12733916.6A patent/EP2663189B1/en active Active
- 2012-01-11 SG SG10201600077RA patent/SG10201600077RA/en unknown
- 2012-02-08 US US13/368,434 patent/US20120258933A1/en not_active Abandoned
-
2013
- 2013-06-06 ZA ZA2013/04139A patent/ZA201304139B/en unknown
- 2013-06-20 IL IL227097A patent/IL227097B/en active IP Right Grant
-
2015
- 2015-01-06 US US14/590,143 patent/US20150119337A1/en not_active Abandoned
- 2015-08-20 US US14/831,261 patent/US20160022641A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,694 patent/US20160375086A1/en not_active Abandoned
- 2016-12-20 US US15/385,205 patent/US10449226B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 《Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenibexhibits strong antiproliferative action in human cholangiocarcinoma》;antoni castells;《world journal of gastroenterology》;20070907;第13卷(第33期);第4413-4536页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391027A1 (ru) | 2014-01-30 |
| EP2663189B1 (en) | 2018-07-04 |
| CN103298345A (zh) | 2013-09-11 |
| JP2014507412A (ja) | 2014-03-27 |
| US20130288984A1 (en) | 2013-10-31 |
| WO2012097021A1 (en) | 2012-07-19 |
| SG10201600077RA (en) | 2016-02-26 |
| MX356704B (es) | 2018-06-11 |
| AU2012205601A1 (en) | 2013-08-01 |
| US20160022641A1 (en) | 2016-01-28 |
| IL227097B (en) | 2018-02-28 |
| JP6100700B2 (ja) | 2017-03-22 |
| KR20140053836A (ko) | 2014-05-08 |
| EA029000B1 (ru) | 2018-01-31 |
| EP2663189A4 (en) | 2014-06-11 |
| SG191724A1 (en) | 2013-08-30 |
| EP2663189A1 (en) | 2013-11-20 |
| ES2689760T3 (es) | 2018-11-15 |
| BR112013017722A2 (pt) | 2016-07-12 |
| US10449226B2 (en) | 2019-10-22 |
| ZA201304139B (en) | 2014-02-26 |
| CA2824201A1 (en) | 2012-07-19 |
| US20120258933A1 (en) | 2012-10-11 |
| AU2012205601B2 (en) | 2016-03-24 |
| MX2013008074A (es) | 2013-08-09 |
| US20170100449A1 (en) | 2017-04-13 |
| US20150119337A1 (en) | 2015-04-30 |
| US20160375086A1 (en) | 2016-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103298345B (zh) | 组合 | |
| EP2572199B1 (en) | Combination | |
| AU2010303363B2 (en) | Combination | |
| AU2010303364B2 (en) | Combination | |
| US20150094283A1 (en) | Combination | |
| US20150272950A1 (en) | Combination | |
| AU2013334943A1 (en) | Combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151022 Address after: Basel, Switzerland Applicant after: NOVARTIS AG Address before: Basel, Switzerland Applicant before: NOVA LABORATORIES SDN BHD Effective date of registration: 20151022 Address after: Basel, Switzerland Applicant after: NOVA LABORATORIES SDN BHD Address before: American Pennsylvania Applicant before: GLAXOSMITHKLINE LLC |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |